Earnings — page 10
Ziff Davis Posts EPS Rebound as Revenue Declines
Free cash flow doubled from a year earlier to $54.0 million.
Wendy’s Withdraws Outlook as U.S. Sales Slide
Second-quarter revenue rose 1.7% to $570.6 million even as restaurant traffic remained under pressure.
Vistra Reaffirms 2026 Outlook After Helix and Cogentrix
Ongoing Operations Adjusted EBITDA reached $1,767 million, up more than 30% from a year earlier, as the company locked in 2026 volumes and kept its $6.8 billion to $7.6 billion range.
Take-Two Bookings Slip as Mobile Revenue Retreats
The videogame publisher recorded a $43.4 million impairment charge after halting an unannounced title.
Treace Lifts 2026 Sales Floor After Narrower Revenue Drop
Second-quarter sales were $45.4 million, a 4% year-over-year decline that improved from the first quarter’s 10% drop.
Interface Lifts Outlook as Margins Widen
Second-quarter net sales rose 5.4% to $395.7 million.
Tredegar Extrusions Profit Recovers After a First-Quarter Dip
Aluminum Extrusions EBITDA from ongoing operations reached $14.5 million in the second quarter, and the company said a $4.9 million FIFO aluminum benefit that lifted the year-over-year comparison is expected to be substantially neutralized in the third quarter.
Spectrum Brands Swings to Loss on HPC Impairment Despite Sales Surge
Spectrum Brands Holdings posted a $20.3 million net loss in its fiscal third quarter even as net sales rose 7.7% and adjusted EBITDA more than doubled.
Fluor Awards Jump as Revenue Returns to Growth
Adjusted EBITDA rose to $149 million, more than doubling from the first quarter.
Embecta Raises Profit Outlook After Rebound From March Slump
Embecta raised its adjusted earnings forecast to $1.80 to $1.90 a share for fiscal 2026 while holding its reported revenue guidance steady.
Ellington Financial's Profit Slides as Litigation Gain Fades
Ellington Financial reported net income of $54.4 million, or $0.43 a share, for the second quarter of 2026, down from $95.5 million a year earlier as one-time gains rolled off.
Artesian's Wastewater Mix Widens as Water Growth Cools
Second-quarter revenue reached $30.7 million as other utility operating revenue rose 16.0% and water sales rose 5.8%.
Zoetis Cuts Outlook as U.S. Pet-Drug Weakness Persists
The animal-health company lowered its full-year adjusted earnings forecast to $6.15 to $6.25 a share.
Zentalis Completes DENALI Enrollment, Pushes Readout to 2027
Cash, cash equivalents and marketable securities stood at $174.6 million as of June 30, 2026, which the company said funds operations into late 2027.
Whitehawk Extends Cash Runway Into Second Half of 2028
Cash, cash equivalents and short-term investments reached $190.0 million after an $87.5 million May private placement, and the company said that balance is anticipated to fund operations into 2H 2028.
Warner Bros. Discovery Profit Craters Ahead of Paramount Deal
Warner Bros. Discovery (WBD) reported net income tumbled 91% to $149 million as Studios weakness deepened even while streaming carried the quarter.
Voyager’s Alzheimer’s Gene Therapy Cleared For Human Testing
Voyager ended June with $148.8 million in liquid resources and said it expects two Alzheimer’s development milestones in the fourth quarter.
TechTarget Reverses First-Quarter Growth and Restates 2026 Targets
Second-quarter revenue was $116.1 million, down 3.2% from a year earlier, after a 2.1% year-over-year increase in the first quarter.
Targa Posts Record EBITDA as Fee-Based Growth Accelerates
Second-quarter adjusted EBITDA reached $1.603 billion, up 14% sequentially.
TriSalus Restores Sequential Revenue After Expansion Dip
TriNav sales reached $11.4 million in the second quarter as the company kept 2026 guidance at $54 million to $57 million.
Molson Coors Volume Slide Deepens as Costs Escalate
Molson Coors Beverage (TAP-A) reported second-quarter net sales fell 3.3% to $3.10 billion as volume declined 5.4% and mark-to-market commodity losses cut into profit.
Silvaco Posts First Non-GAAP Operating Profit in Two Years
Second-quarter revenue of $17.8 million rose 48% after 26% growth in the first quarter, and non-GAAP operating income reached $0.6 million.
SIGA Completes 19C Stockpile Deliveries After Quiet Quarters
The smallpox-drug maker booked $41.0 million of revenue and $12.5 million of net income in the three months ended June 30, 2026, after two consecutive quarters of losses.
Runway Growth Restores Net Investment Income After SWK Close
Net investment income was $18.2 million, or $0.43 a share, as the specialty finance company closed the SWK Holdings deal and lifted the portfolio to $1.2 billion.
Cartesian Extends Cash Runway Into 2028 After K2HV Loan
Cash, cash equivalents and restricted cash stood at $149.3 million after a $50 million K2 HealthVentures term loan and $19.3 million of year-to-date ATM proceeds.
BRC Group's Core Operating Profit Reaches Highest Since Late 2023
Operating Adjusted EBITDA was $66.0 million in the second quarter as net income available to common shareholders was $18.5 million.
AVITA Medical Raises 2026 Guidance After Record Quarter
Second-quarter revenue hit a record $21.7 million, up 18% from a year earlier, and the company lifted its full-year range to $86 million to $89 million.
Ready Capital’s Distributable Loss Narrowed After First-Quarter Widening
Ready Capital reported a distributable loss of $0.47 a share for the June quarter while keeping its focus on fourth-quarter debt maturities.
CPI Card Group Lifts 2026 Revenue and Cash-Flow Outlook
Second-quarter revenue rose 15% to $149.2 million as the company raised 2026 free-cash-flow guidance to $45 million–$50 million.
Palladyne AI Reiterates 2026 Guidance After Record Quarter
Second-quarter revenue reached $5.8 million, and the company kept its $24 million to $27 million full-year outlook intact.
Montauk's Second-Quarter Revenue Growth Accelerates
Revenue reached $54.0 million, up 19.7% from a year earlier, as Adjusted EBITDA rose 144.5% to $12.3 million.
Lee Raises Fiscal 2026 Ebitda Outlook After Profit Return
The company now expects 22% to 28% year-over-year Adjusted EBITDA growth, after a $5 million net income in the quarter ended June 28, 2026.
Lifetime Brands Raises 2026 Earnings Outlook After Tariff Refunds
The home-products marketer booked a $40.1 million tariff refund, swung to $19.6 million of net income, or $0.87 a share, and lifted full-year profit guidance.
Lineage Chose Animal Testing for New Corneal Cell Therapy
The biotechnology developer reported $4.8 million in quarterly research spending as its new COR1 eye-disease program cleared internal criteria for further preclinical work.
Kenvue Sales Rise as Volume Growth Returns
Adjusted earnings rose 7% to $0.31 a share despite pressure from tariffs and inflation.
Korro Bio Adds Drug Candidate for Genetic Liver and Lung Disease
The RNA-editing drug developer ended June with $137.9 million in cash and securities, which it expects to fund operations into the second half of 2028.
Keurig Dr Pepper Profit Rebounded After JDE Peet’s Acquisition
Net sales reached $7.31 billion after the April acquisition transformed the beverage maker’s business.
Howmet Raises Outlook as Aerospace Demand Accelerates
Second-quarter revenue reached $2.547 billion, topping the high end of Howmet’s prior guidance by $137 million.
Friedman Posts Record Volume and Lifts Earnings
Net earnings reached $12.8 million, or $1.79 a share, on sales of $240.0 million as volume hit about 206,000 tons.
Expensify Lifts Full-Year Free Cash Flow Outlook
The company now estimates $12.0 million to $14.0 million of free cash flow for the year ending December 31, 2026, after a $6.4 million second-quarter print.
Precision BioSciences Reports First Biopsy Proof of cccDNA Elimination
Liver biopsies in ELIMINATE-B showed a 1-log cccDNA drop with under 1% remaining after two PBGENE-HBV doses, and cash stood at $112.4 million at June 30.
Cerence Authorizes First Share Repurchase Program
The board approved up to $30 million of buybacks as third-quarter revenue reached $69.6 million and Adjusted EBITDA rose 50% to $13.5 million.
Corbus Wins FDA Clearance for CRB-701 Phase 3 Trial
Cash of $117.9 million is expected to fund operations into 2028 as the company prepares two September clinical milestones.
Commerce.com's Revenue Growth Stalls After First-Quarter Rebound
Second-quarter revenue was $84.5 million, up 0.1% from a year earlier, after 5% growth in the first quarter, as subscription solutions turned negative.
Citizens Swings to a Loss as Endowment Maturities Recede
Direct insurance premiums reached $48.1 million in the second quarter, the fifteenth straight year-over-year gain in first-year premium.
Blend Labs Growth Cools After a Faster First Quarter
Second-quarter revenue was $33.8 million, up 7% from a year earlier, as non-GAAP operating income reached $7.0 million.
Becton Dickinson Raises Profit Outlook as Revenue Grows
Adjusted earnings from continuing operations increased to $3.23 a share.
Artiva Wins RMAT for AlloNK in Refractory Rheumatoid Arthritis
Cash, cash equivalents and investments stood at $349.4 million as of June 30, 2026, after an approximately $300 million May offering the company said will fund operations into 2029.
ALX Oncology Cash Reaches $153.4 Million After Refinancing
The clinical-stage biotech said cash, cash equivalents and investments of $153.4 million as of June 30, 2026, are sufficient to fund planned operations through the first half of 2028.
Alta Equipment Tightens 2026 Adjusted EBITDA Range
The equipment dealer now expects full-year Adjusted EBITDA of $167.5 million to $177.5 million after second-quarter Adjusted EBITDA of $48.6 million.